Reviews Epogen


No reviews yet.

Epogen Drug Description
EPOGEN®
(epoetin alfa) for Injection

WARNINGS
INCREASED MORTALITY, SERIOUS CARDIOVASCULAR EVENTS, THROMBOEMBOLIC EVENTS, STROKE and INCREASED RISK OF TUMOR PROGRESSION OR RECURRENCE
Chronic Renal Failure:

In clinical studies, patients experienced greater risks for death, serious
cardiovascular events, and stroke when administered erythropoiesis-stimulating
agents (ESAs) to target hemoglobin levels of 13 g/dL and above.
Individualize dosing to achieve and maintain hemoglobin levels within
the range of 10 to 12 g/dL.

Cancer:

ESAs shortened overall survival and/or increased the risk of tumor
progression or recurrence in some clinical studies in patients with breast,
non-small cell lung, head and neck, lymphoid, and cervical cancers (see
WARNINGS: Table 1).
To decrease these risks, as well as the risk of serious cardio- and thrombovascular
events, use the lowest dose needed to avoid red blood cell transfusion.
Because of these risks, prescribers and hospitals must enroll in and
comply with the ESA APPRISE Oncology Program to prescribe and/or dispense
EPOGEN® to patients with cancer. To enroll in the ESA APPRISE Oncology
Program, visit www.esa-apprise.com or call 1-866-284-8089 for further assistance.

Use ESAs only for treatment of anemia due to concomitant myelosuppressive
chemotherapy.
ESAs are not indicated for patients receiving myelosuppressive therapy
when the anticipated outcome is cure.
Discontinue following the completion of a chemotherapy course.

Perisurgery: EPOGEN® increased the rate of deep venous thromboses in
patients not receiving prophylactic anticoagulation. Consider deep venous thrombosis prophylaxis.
(See WARNINGS: Increased Mortality, Serious
Cardiovascular Events, Thromboembolic Events, and Stroke, WARNINGS:
Increased Mortality and/or Increased Risk of Tumor Progression or Recurrence,
INDICATIONS AND USAGE, and DOSAGE
AND ADMINISTRATION.)

DRUG DESCRIPTION



What are the possible side effects of epoetin alfa (Epogen, Procrit)?

Contact your doctor if you feel weak, lightheaded, or short of breath, or if your skin looks pale. These may be signs that your body has stopped responding to this medication.
Epoetin alfa can increase your risk of life-threatening heart or circulation problems, including heart attack or stroke. This risk will increase the longer you use epoetin alfa. Seek emergency medical help if you have symptoms of heart or circulation problems, such as:

chest pain or heavy feeling, pain...
Read All Potential Side Effects for Epogen »




Erythropoietin is a glycoprotein which stimulates red blood cell production.
It is produced in the kidney and stimulates the division and differentiation
of committed erythroid progenitors in the bone marrow. EPOGEN® (Epoetin
alfa), a 165 amino acid glycoprotein manufactured by recombinant DNA technology,
has the same biological effects as endogenous erythropoietin.1 It
has a molecular weight of 30,400 daltons and is produced by mammalian cells
into which the human erythropoietin gene has been introduced. The product contains
the identical amino acid sequence of isolated natural erythropoietin.
EPOGEN® is formulated as a sterile, colorless liquid in an isotonic sodium
chloride/sodium citrate buffered solution or a sodium chloride/sodium phosphate
buffered solution for intravenous (IV) or subcutaneous (SC) administration.
Single-dose, Preservative-free Vial: Each 1 mL of solution contains
2000, 3000, 4000 or 10,000 Units of Epoetin alfa, 2.5 mg Albumin (Human), 5.8
mg sodium citrate, 5.8 mg sodium chloride, and 0.06 mg citric acid in Water
for Injection, USP (pH 6.9 ± 0.3). This formulation contains no preservative.
Single-dose, Preservative-free Vial: 1 mL (40,000 Units/mL). Each 1
mL of solution contains 40,000 Units of Epoetin alfa, 2.5 mg Albumin (Human),
1.2 mg sodium phosphate monobasic monohydrate, 1.8 mg sodium phosphate dibasic
anhydrate, 0.7 mg sodium citrate, 5.8 mg sodium chloride, and 6.8 mcg citric
acid in Water for Injection, USP (pH 6.9 ± 0.3). This formulation contains
no preservative.
Multidose, Preserved Vial: 2 mL (20,000 Units, 10,000 Units/mL). Each
1 mL of solution contains 10,000 Units of Epoetin alfa, 2.5 mg Albumin (Human),
1.3 mg sodium citrate, 8.2 mg sodium chloride, 0.11 mg citric acid, and 1% benzyl
alcohol as preservative in Water for Injection, USP (pH 6.1 ± 0.3).
Multidose, Preserved Vial: 1 mL (20,000 Units/mL). Each 1 mL of solution
contains 20,000 Units of Epoetin alfa, 2.5 mg Albumin (Human), 1.3 mg sodium
citrate, 8.2 mg sodium chloride, 0.11 mg citric acid, and 1% benzyl alcohol
as preservative in Water for Injection, USP (pH 6.1 ± 0.3).
1. Egrie JC, Strickland TW, Lane J, et al. Characterization
and Biological Effects of Recombinant Human Erythropoietin. Immunobiol. 1986;72:213-224.Last reviewed on RxList: 2/25/2010




Epogen Drug Description
EPOGEN®
(epoetin alfa) for Injection

WARNINGS
INCREASED MORTALITY, SERIOUS CARDIOVASCULAR EVENTS, THROMBOEMBOLIC EVENTS, STROKE and INCREASED RISK OF TUMOR PROGRESSION OR RECURRENCE
Chronic Renal Failure:

In clinical studies, patients experienced greater risks for death, serious
cardiovascular events, and stroke when administered erythropoiesis-stimulating
agents (ESAs) to target hemoglobin levels of 13 g/dL and above.
Individualize dosing to achieve and maintain hemoglobin levels within
the range of 10 to 12 g/dL.

Cancer:

ESAs shortened overall survival and/or increased the risk of tumor
progression or recurrence in some clinical studies in patients with breast,
non-small cell lung, head and neck, lymphoid, and cervical cancers (see
WARNINGS: Table 1).
To decrease these risks, as well as the risk of serious cardio- and thrombovascular
events, use the lowest dose needed to avoid red blood cell transfusion.
Because of these risks, prescribers and hospitals must enroll in and
comply with the ESA APPRISE Oncology Program to prescribe and/or dispense
EPOGEN® to patients with cancer. To enroll in the ESA APPRISE Oncology
Program, visit www.esa-apprise.com or call 1-866-284-8089 for further assistance.

Use ESAs only for treatment of anemia due to concomitant myelosuppressive
chemotherapy.
ESAs are not indicated for patients receiving myelosuppressive therapy
when the anticipated outcome is cure.
Discontinue following the completion of a chemotherapy course.

Perisurgery: EPOGEN® increased the rate of deep venous thromboses in
patients not receiving prophylactic anticoagulation. Consider deep venous thrombosis prophylaxis.
(See WARNINGS: Increased Mortality, Serious
Cardiovascular Events, Thromboembolic Events, and Stroke, WARNINGS:
Increased Mortality and/or Increased Risk of Tumor Progression or Recurrence,
INDICATIONS AND USAGE, and DOSAGE
AND ADMINISTRATION.)

DRUG DESCRIPTION



What are the possible side effects of epoetin alfa (Epogen, Procrit)?

Contact your doctor if you feel weak, lightheaded, or short of breath, or if your skin looks pale. These may be signs that your body has stopped responding to this medication.
Epoetin alfa can increase your risk of life-threatening heart or circulation problems, including heart attack or stroke. This risk will increase the longer you use epoetin alfa. Seek emergency medical help if you have symptoms of heart or circulation problems, such as:

chest pain or heavy feeling, pain...
Read All Potential Side Effects for Epogen »




Erythropoietin is a glycoprotein which stimulates red blood cell production.
It is produced in the kidney and stimulates the division and differentiation
of committed erythroid progenitors in the bone marrow. EPOGEN® (Epoetin
alfa), a 165 amino acid glycoprotein manufactured by recombinant DNA technology,
has the same biological effects as endogenous erythropoietin.1 It
has a molecular weight of 30,400 daltons and is produced by mammalian cells
into which the human erythropoietin gene has been introduced. The product contains
the identical amino acid sequence of isolated natural erythropoietin.
EPOGEN® is formulated as a sterile, colorless liquid in an isotonic sodium
chloride/sodium citrate buffered solution or a sodium chloride/sodium phosphate
buffered solution for intravenous (IV) or subcutaneous (SC) administration.
Single-dose, Preservative-free Vial: Each 1 mL of solution contains
2000, 3000, 4000 or 10,000 Units of Epoetin alfa, 2.5 mg Albumin (Human), 5.8
mg sodium citrate, 5.8 mg sodium chloride, and 0.06 mg citric acid in Water
for Injection, USP (pH 6.9 ± 0.3). This formulation contains no preservative.
Single-dose, Preservative-free Vial: 1 mL (40,000 Units/mL). Each 1
mL of solution contains 40,000 Units of Epoetin alfa, 2.5 mg Albumin (Human),
1.2 mg sodium phosphate monobasic monohydrate, 1.8 mg sodium phosphate dibasic
anhydrate, 0.7 mg sodium citrate, 5.8 mg sodium chloride, and 6.8 mcg citric
acid in Water for Injection, USP (pH 6.9 ± 0.3). This formulation contains
no preservative.
Multidose, Preserved Vial: 2 mL (20,000 Units, 10,000 Units/mL). Each
1 mL of solution contains 10,000 Units of Epoetin alfa, 2.5 mg Albumin (Human),
1.3 mg sodium citrate, 8.2 mg sodium chloride, 0.11 mg citric acid, and 1% benzyl
alcohol as preservative in Water for Injection, USP (pH 6.1 ± 0.3).
Multidose, Preserved Vial: 1 mL (20,000 Units/mL). Each 1 mL of solution
contains 20,000 Units of Epoetin alfa, 2.5 mg Albumin (Human), 1.3 mg sodium
citrate, 8.2 mg sodium chloride, 0.11 mg citric acid, and 1% benzyl alcohol
as preservative in Water for Injection, USP (pH 6.1 ± 0.3).
1. Egrie JC, Strickland TW, Lane J, et al. Characterization
and Biological Effects of Recombinant Human Erythropoietin. Immunobiol. 1986;72:213-224.Last reviewed on RxList: 2/25/2010




Epogen Drug Description
EPOGEN®
(epoetin alfa) for Injection

WARNINGS
INCREASED MORTALITY, SERIOUS CARDIOVASCULAR EVENTS, THROMBOEMBOLIC EVENTS, STROKE and INCREASED RISK OF TUMOR PROGRESSION OR RECURRENCE
Chronic Renal Failure:

In clinical studies, patients experienced greater risks for death, serious
cardiovascular events, and stroke when administered erythropoiesis-stimulating
agents (ESAs) to target hemoglobin levels of 13 g/dL and above.
Individualize dosing to achieve and maintain hemoglobin levels within
the range of 10 to 12 g/dL.

Cancer:

ESAs shortened overall survival and/or increased the risk of tumor
progression or recurrence in some clinical studies in patients with breast,
non-small cell lung, head and neck, lymphoid, and cervical cancers (see
WARNINGS: Table 1).
To decrease these risks, as well as the risk of serious cardio- and thrombovascular
events, use the lowest dose needed to avoid red blood cell transfusion.
Because of these risks, prescribers and hospitals must enroll in and
comply with the ESA APPRISE Oncology Program to prescribe and/or dispense
EPOGEN® to patients with cancer. To enroll in the ESA APPRISE Oncology
Program, visit www.esa-apprise.com or call 1-866-284-8089 for further assistance.

Use ESAs only for treatment of anemia due to concomitant myelosuppressive
chemotherapy.
ESAs are not indicated for patients receiving myelosuppressive therapy
when the anticipated outcome is cure.
Discontinue following the completion of a chemotherapy course.

Perisurgery: EPOGEN® increased the rate of deep venous thromboses in
patients not receiving prophylactic anticoagulation. Consider deep venous thrombosis prophylaxis.
(See WARNINGS: Increased Mortality, Serious
Cardiovascular Events, Thromboembolic Events, and Stroke, WARNINGS:
Increased Mortality and/or Increased Risk of Tumor Progression or Recurrence,
INDICATIONS AND USAGE, and DOSAGE
AND ADMINISTRATION.)

DRUG DESCRIPTION



What are the possible side effects of epoetin alfa (Epogen, Procrit)?

Contact your doctor if you feel weak, lightheaded, or short of breath, or if your skin looks pale. These may be signs that your body has stopped responding to this medication.
Epoetin alfa can increase your risk of life-threatening heart or circulation problems, including heart attack or stroke. This risk will increase the longer you use epoetin alfa. Seek emergency medical help if you have symptoms of heart or circulation problems, such as:

chest pain or heavy feeling, pain...
Read All Potential Side Effects for Epogen »




Erythropoietin is a glycoprotein which stimulates red blood cell production.
It is produced in the kidney and stimulates the division and differentiation
of committed erythroid progenitors in the bone marrow. EPOGEN® (Epoetin
alfa), a 165 amino acid glycoprotein manufactured by recombinant DNA technology,
has the same biological effects as endogenous erythropoietin.1 It
has a molecular weight of 30,400 daltons and is produced by mammalian cells
into which the human erythropoietin gene has been introduced. The product contains
the identical amino acid sequence of isolated natural erythropoietin.
EPOGEN® is formulated as a sterile, colorless liquid in an isotonic sodium
chloride/sodium citrate buffered solution or a sodium chloride/sodium phosphate
buffered solution for intravenous (IV) or subcutaneous (SC) administration.
Single-dose, Preservative-free Vial: Each 1 mL of solution contains
2000, 3000, 4000 or 10,000 Units of Epoetin alfa, 2.5 mg Albumin (Human), 5.8
mg sodium citrate, 5.8 mg sodium chloride, and 0.06 mg citric acid in Water
for Injection, USP (pH 6.9 ± 0.3). This formulation contains no preservative.
Single-dose, Preservative-free Vial: 1 mL (40,000 Units/mL). Each 1
mL of solution contains 40,000 Units of Epoetin alfa, 2.5 mg Albumin (Human),
1.2 mg sodium phosphate monobasic monohydrate, 1.8 mg sodium phosphate dibasic
anhydrate, 0.7 mg sodium citrate, 5.8 mg sodium chloride, and 6.8 mcg citric
acid in Water for Injection, USP (pH 6.9 ± 0.3). This formulation contains
no preservative.
Multidose, Preserved Vial: 2 mL (20,000 Units, 10,000 Units/mL). Each
1 mL of solution contains 10,000 Units of Epoetin alfa, 2.5 mg Albumin (Human),
1.3 mg sodium citrate, 8.2 mg sodium chloride, 0.11 mg citric acid, and 1% benzyl
alcohol as preservative in Water for Injection, USP (pH 6.1 ± 0.3).
Multidose, Preserved Vial: 1 mL (20,000 Units/mL). Each 1 mL of solution
contains 20,000 Units of Epoetin alfa, 2.5 mg Albumin (Human), 1.3 mg sodium
citrate, 8.2 mg sodium chloride, 0.11 mg citric acid, and 1% benzyl alcohol
as preservative in Water for Injection, USP (pH 6.1 ± 0.3).
1. Egrie JC, Strickland TW, Lane J, et al. Characterization
and Biological Effects of Recombinant Human Erythropoietin. Immunobiol. 1986;72:213-224.Last reviewed on RxList: 2/25/2010




Epogen Drug Description
EPOGEN®
(epoetin alfa) for Injection

WARNINGS
INCREASED MORTALITY, SERIOUS CARDIOVASCULAR EVENTS, THROMBOEMBOLIC EVENTS, STROKE and INCREASED RISK OF TUMOR PROGRESSION OR RECURRENCE
Chronic Renal Failure:

In clinical studies, patients experienced greater risks for death, serious
cardiovascular events, and stroke when administered erythropoiesis-stimulating
agents (ESAs) to target hemoglobin levels of 13 g/dL and above.
Individualize dosing to achieve and maintain hemoglobin levels within
the range of 10 to 12 g/dL.

Cancer:

ESAs shortened overall survival and/or increased the risk of tumor
progression or recurrence in some clinical studies in patients with breast,
non-small cell lung, head and neck, lymphoid, and cervical cancers (see
WARNINGS: Table 1).
To decrease these risks, as well as the risk of serious cardio- and thrombovascular
events, use the lowest dose needed to avoid red blood cell transfusion.
Because of these risks, prescribers and hospitals must enroll in and
comply with the ESA APPRISE Oncology Program to prescribe and/or dispense
EPOGEN® to patients with cancer. To enroll in the ESA APPRISE Oncology
Program, visit www.esa-apprise.com or call 1-866-284-8089 for further assistance.

Use ESAs only for treatment of anemia due to concomitant myelosuppressive
chemotherapy.
ESAs are not indicated for patients receiving myelosuppressive therapy
when the anticipated outcome is cure.
Discontinue following the completion of a chemotherapy course.

Perisurgery: EPOGEN® increased the rate of deep venous thromboses in
patients not receiving prophylactic anticoagulation. Consider deep venous thrombosis prophylaxis.
(See WARNINGS: Increased Mortality, Serious
Cardiovascular Events, Thromboembolic Events, and Stroke, WARNINGS:
Increased Mortality and/or Increased Risk of Tumor Progression or Recurrence,
INDICATIONS AND USAGE, and DOSAGE
AND ADMINISTRATION.)

DRUG DESCRIPTION



What are the possible side effects of epoetin alfa (Epogen, Procrit)?

Contact your doctor if you feel weak, lightheaded, or short of breath, or if your skin looks pale. These may be signs that your body has stopped responding to this medication.
Epoetin alfa can increase your risk of life-threatening heart or circulation problems, including heart attack or stroke. This risk will increase the longer you use epoetin alfa. Seek emergency medical help if you have symptoms of heart or circulation problems, such as:

chest pain or heavy feeling, pain...
Read All Potential Side Effects for Epogen »




Erythropoietin is a glycoprotein which stimulates red blood cell production.
It is produced in the kidney and stimulates the division and differentiation
of committed erythroid progenitors in the bone marrow. EPOGEN® (Epoetin
alfa), a 165 amino acid glycoprotein manufactured by recombinant DNA technology,
has the same biological effects as endogenous erythropoietin.1 It
has a molecular weight of 30,400 daltons and is produced by mammalian cells
into which the human erythropoietin gene has been introduced. The product contains
the identical amino acid sequence of isolated natural erythropoietin.
EPOGEN® is formulated as a sterile, colorless liquid in an isotonic sodium
chloride/sodium citrate buffered solution or a sodium chloride/sodium phosphate
buffered solution for intravenous (IV) or subcutaneous (SC) administration.
Single-dose, Preservative-free Vial: Each 1 mL of solution contains
2000, 3000, 4000 or 10,000 Units of Epoetin alfa, 2.5 mg Albumin (Human), 5.8
mg sodium citrate, 5.8 mg sodium chloride, and 0.06 mg citric acid in Water
for Injection, USP (pH 6.9 ± 0.3). This formulation contains no preservative.
Single-dose, Preservative-free Vial: 1 mL (40,000 Units/mL). Each 1
mL of solution contains 40,000 Units of Epoetin alfa, 2.5 mg Albumin (Human),
1.2 mg sodium phosphate monobasic monohydrate, 1.8 mg sodium phosphate dibasic
anhydrate, 0.7 mg sodium citrate, 5.8 mg sodium chloride, and 6.8 mcg citric
acid in Water for Injection, USP (pH 6.9 ± 0.3). This formulation contains
no preservative.
Multidose, Preserved Vial: 2 mL (20,000 Units, 10,000 Units/mL). Each
1 mL of solution contains 10,000 Units of Epoetin alfa, 2.5 mg Albumin (Human),
1.3 mg sodium citrate, 8.2 mg sodium chloride, 0.11 mg citric acid, and 1% benzyl
alcohol as preservative in Water for Injection, USP (pH 6.1 ± 0.3).
Multidose, Preserved Vial: 1 mL (20,000 Units/mL). Each 1 mL of solution
contains 20,000 Units of Epoetin alfa, 2.5 mg Albumin (Human), 1.3 mg sodium
citrate, 8.2 mg sodium chloride, 0.11 mg citric acid, and 1% benzyl alcohol
as preservative in Water for Injection, USP (pH 6.1 ± 0.3).
1. Egrie JC, Strickland TW, Lane J, et al. Characterization
and Biological Effects of Recombinant Human Erythropoietin. Immunobiol. 1986;72:213-224.Last reviewed on RxList: 2/25/2010




Epogen Drug Description
EPOGEN®
(epoetin alfa) for Injection

WARNINGS
INCREASED MORTALITY, SERIOUS CARDIOVASCULAR EVENTS, THROMBOEMBOLIC EVENTS, STROKE and INCREASED RISK OF TUMOR PROGRESSION OR RECURRENCE
Chronic Renal Failure:

In clinical studies, patients experienced greater risks for death, serious
cardiovascular events, and stroke when administered erythropoiesis-stimulating
agents (ESAs) to target hemoglobin levels of 13 g/dL and above.
Individualize dosing to achieve and maintain hemoglobin levels within
the range of 10 to 12 g/dL.

Cancer:

ESAs shortened overall survival and/or increased the risk of tumor
progression or recurrence in some clinical studies in patients with breast,
non-small cell lung, head and neck, lymphoid, and cervical cancers (see
WARNINGS: Table 1).
To decrease these risks, as well as the risk of serious cardio- and thrombovascular
events, use the lowest dose needed to avoid red blood cell transfusion.
Because of these risks, prescribers and hospitals must enroll in and
comply with the ESA APPRISE Oncology Program to prescribe and/or dispense
EPOGEN® to patients with cancer. To enroll in the ESA APPRISE Oncology
Program, visit www.esa-apprise.com or call 1-866-284-8089 for further assistance.

Use ESAs only for treatment of anemia due to concomitant myelosuppressive
chemotherapy.
ESAs are not indicated for patients receiving myelosuppressive therapy
when the anticipated outcome is cure.
Discontinue following the completion of a chemotherapy course.

Perisurgery: EPOGEN® increased the rate of deep venous thromboses in
patients not receiving prophylactic anticoagulation. Consider deep venous thrombosis prophylaxis.
(See WARNINGS: Increased Mortality, Serious
Cardiovascular Events, Thromboembolic Events, and Stroke, WARNINGS:
Increased Mortality and/or Increased Risk of Tumor Progression or Recurrence,
INDICATIONS AND USAGE, and DOSAGE
AND ADMINISTRATION.)

DRUG DESCRIPTION



What are the possible side effects of epoetin alfa (Epogen, Procrit)?

Contact your doctor if you feel weak, lightheaded, or short of breath, or if your skin looks pale. These may be signs that your body has stopped responding to this medication.
Epoetin alfa can increase your risk of life-threatening heart or circulation problems, including heart attack or stroke. This risk will increase the longer you use epoetin alfa. Seek emergency medical help if you have symptoms of heart or circulation problems, such as:

chest pain or heavy feeling, pain...
Read All Potential Side Effects for Epogen »




Erythropoietin is a glycoprotein which stimulates red blood cell production.
It is produced in the kidney and stimulates the division and differentiation
of committed erythroid progenitors in the bone marrow. EPOGEN® (Epoetin
alfa), a 165 amino acid glycoprotein manufactured by recombinant DNA technology,
has the same biological effects as endogenous erythropoietin.1 It
has a molecular weight of 30,400 daltons and is produced by mammalian cells
into which the human erythropoietin gene has been introduced. The product contains
the identical amino acid sequence of isolated natural erythropoietin.
EPOGEN® is formulated as a sterile, colorless liquid in an isotonic sodium
chloride/sodium citrate buffered solution or a sodium chloride/sodium phosphate
buffered solution for intravenous (IV) or subcutaneous (SC) administration.
Single-dose, Preservative-free Vial: Each 1 mL of solution contains
2000, 3000, 4000 or 10,000 Units of Epoetin alfa, 2.5 mg Albumin (Human), 5.8
mg sodium citrate, 5.8 mg sodium chloride, and 0.06 mg citric acid in Water
for Injection, USP (pH 6.9 ± 0.3). This formulation contains no preservative.
Single-dose, Preservative-free Vial: 1 mL (40,000 Units/mL). Each 1
mL of solution contains 40,000 Units of Epoetin alfa, 2.5 mg Albumin (Human),
1.2 mg sodium phosphate monobasic monohydrate, 1.8 mg sodium phosphate dibasic
anhydrate, 0.7 mg sodium citrate, 5.8 mg sodium chloride, and 6.8 mcg citric
acid in Water for Injection, USP (pH 6.9 ± 0.3). This formulation contains
no preservative.
Multidose, Preserved Vial: 2 mL (20,000 Units, 10,000 Units/mL). Each
1 mL of solution contains 10,000 Units of Epoetin alfa, 2.5 mg Albumin (Human),
1.3 mg sodium citrate, 8.2 mg sodium chloride, 0.11 mg citric acid, and 1% benzyl
alcohol as preservative in Water for Injection, USP (pH 6.1 ± 0.3).
Multidose, Preserved Vial: 1 mL (20,000 Units/mL). Each 1 mL of solution
contains 20,000 Units of Epoetin alfa, 2.5 mg Albumin (Human), 1.3 mg sodium
citrate, 8.2 mg sodium chloride, 0.11 mg citric acid, and 1% benzyl alcohol
as preservative in Water for Injection, USP (pH 6.1 ± 0.3).
1. Egrie JC, Strickland TW, Lane J, et al. Characterization
and Biological Effects of Recombinant Human Erythropoietin. Immunobiol. 1986;72:213-224.Last reviewed on RxList: 2/25/2010





Other reviews about Epogen on wordpress

Conflicts of Interest or Bribery--what about the patient?
  by medicynic
Millions of dollars in rebates from drug companies to doctors for the use of Aranesp and Epogen are reported in the Times today. From Marketwatch--"Federal laws bar drug companies […]


Amgen: Today's Review Critical For Anemia Reimbursements (AMGN)
  by 247wallst
Amgen (NASDAQ:AMGN) has a huge day ahead of it.  The biotech giant is presenting data today on the appropriateuse of Erythropoiesis Stimulating Agents in Chronic RenalFailure patients to […]


What Does Your Prescription Label Say?
  by DaVita
The Food and Drug Administration (FDA) has just issued a "black box" warning for anemia drugs prescribed for cancer and kidney failure patients. The three common known drugs […]


Anemia meds and cancer patients do not mix...
  by Mooserx
A recent study from the Journal of the American Medical Association has confirmed that the use of Epogen, Procrit, and Arenesp to treat anemia in cancer patients has […]


Epogen, Aranesp and Procrit--Tumors grow faster
  by medicynic
Epogen and Procrit have been used for about 20 years. They have been shamelessly marketed as an adjuvant to treat fatigue, rather than therapy for cancers. They were […]


Amgen
  by Deepak
Amgen Amgen is the largest independent Biotech company to come out of the Biotech Revolution of the 1980's. It is one of the most future-oriented firms in the stable […]


Amgen Recalls Anemia Drugs Due To Glass Flakes
  by cbsjenn
THOUSAND OAKS (AP) — Amgen Inc. is recalling some lots of its Epogen and Procrit anemia treatments because they may contain glass flakes. The Thousand Oaks, Calif., biotechnology company says […]


Epogen and Procrit: Voluntary Recall
  by infusionnurse
Certain lots of Epogen and Procrit (Epoetin alfa) vials are being recalled as a precaution, because the vials may contain extremely thin glass flakes (lamellae) that are barely […]


FDA MedWatch - Epogen and Procrit (epoetin alfa): Recall - Particulate Matter in Vials
  by irbtipoftheweek
ISSUE: Amgen and FDA notified healthcare professionals that certain lots of Epogen and Procrit (Epoetin alfa) vials are being recalled as a precaution, because the vials may contain […]


What are national interests
  by wisdomiwm
It is better than investing in another company and then having no conversion at all, portable media devices are good tools for listening to your audio books, but […]



Other reviews about Epogen on web:

Indication. EPOGEN ® (Epoetin alfa) is used to treat a lower than normal number of red blood cells (anemia) caused by chronic kidney failure in patients on dialysis. EPOGEN® (epoetin alfa) recombinant


Learn about the prescription medication Epogen (Epoetin Alfa), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient labeling. Epogen (Epoetin Alfa) Drug Information: Uses, Side Effects, Drug ...


Epogen (epoetin alfa) is used to treat anemia (a lack of red blood cells in the body). Includes Epogen side effects, interactions and indications. Epogen Information from Drugs.com


Epoetin is marketed under the trade names Procrit and Epogen. Its annual cost to U.S. patients is $8,447. Adverse effects. Epoetin alfa is well-tolerated. Epoetin alfa - Wikipedia, the free encyclopedia


Accurate, FDA approved Epogen information for healthcare professionals and patients - brought to you by Drugs.com. Epogen Official FDA information, side effects and uses.


Assessing and Managing Anemia in a Patient Who Exhibits Acute Decreased Responsiveness to EPOGEN ® Therapy. Register EPOGEN®(Epoetin alfa) recombinant - For Patients on Dialysis with ...


Explains the medication epoetin alfa (Epogen, Procrit), a drug used to treat anemia (low red blood cell count) that is associated with chronic kidney failure in patients who ... epoetin alfa (Epogen, Procrit) - drug class, medical uses ...


Epogen is a prescription drug used to treat anemia due to chemotherapy, renal failure, or zidovudine. This eMedTV Web page discusses in detail other Epogen uses, explains how the ... Epogen


Epogen is a glycoprotein used to treat anemia in certain patients with kidney failure, patients with HIV taking zidovudine, or cancer patients receiving chemotherapy for at least 2 ... Epogen - drugstore.com. Low prices, side effects, interactions.


Methoxy Polyethylene Glycol-Epoetin Beta (MIRCERA) Brands available in the USA include: Epoetin (Procrit and Epogen). Anemia due to treatment for cancer Erythropoietin - Wikipedia, the free encyclopedia





Featured Reviews

Reviews Tetanus Immune Globulin

BayTet Drug Description BayTet® Tetanus Immune Globulin (Human) Solvent/Detergent Treated 250 Units DRUG DESCRIPTION Tetanus Immune Globulin (Human) BayTet® treated with solvent/detergent is a sterile solution of tetanus hyperimmune...
Read More  |  Review This
Reviews Phenytoin Oral Suspension

Dilantin 125 Drug Description Dilantin-125® (phenytoin) Oral Suspension, USP (NOT FOR PARENTERAL USE) DRUG DESCRIPTION What are the possible side effects of phenytoin? Get emergency medical help if you have any of these...
Read More  |  Review This
Reviews Zoloft

Zoloft Drug Description ZOLOFT® (sertraline hydrochloride) Tablets and Oral Concentrate Suicidality and Antidepressant Drugs Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality)...
Read More  |  Review This
Reviews Prinzide

Prinzide Drug Description PRINZIDE® (lisinopril-hydrochlorothiazide) Tablets USE IN PREGNANCY When used in pregnancy during the second and third trimesters, ACE inhibitors can cause injury and even death to the developing fetus....
Read More  |  Review This
Reviews Fluorometholone Ophthalmic Suspension

FML Drug Description FML® (fluorometholone) Ophthalmic Suspension, USP 0.1% Sterile DRUG DESCRIPTION What are the possible side effects of fluorometholone ophthalmic (Flarex, FML Forte Liquifilm, FML Liquifilm, FML S.O.P.)? Get...
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....